Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis

Current Opinion in Pulmonary Medicine

Volumn 12, Issue 3, 2006, Pages 179-185

  Lalloo, Umesh G ^a,b   Naidoo, Rishendran ^a   Ambaram, Anish ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Department of Medicine ^*  (South Africa)

Author keywords

Lung; Surgery; Tuberculosis

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GAMMA INTERFERON; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NITROIMIDAZOPYRAN DERIVATIVE; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; BCG VACCINE;

CLINICAL TRIAL; DRUG INHIBITION; DRUG TOLERABILITY; ELECTROPHORESIS; HUMAN; IMMUNOMODULATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR HYBRIDIZATION; MULTIDRUG RESISTANCE; NONHUMAN; PATIENT SELECTION; PREVALENCE; RELAPSE; REVIEW; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; LUNG RESECTION; LUNG TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; PNEUMONECTOMY; TUBERCULOSIS VACCINES; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 33745054929     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000219266.27439.52     Document Type: Review

References (43)

1. Balter M. AIDS now world's fourth biggest killer. Science 1999; 284:1101.
2. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organisation. Tubercle 1992; 72:106.
3. O'Brien RJ, Spigelman M. New drugs for tuberculosis: current status and future prospects. Clin Chest Med 2005; 26:327-340. This is an excellent review of emerging new drugs.
4. Bifani P, Mathema B, Campo M, et al. Molecular identification of streptomycin monoresistant Mycobacterium tuberculosis related to multidrug-resistant W strain. Emerg Infect Dis 2001; 7:842-848.
5. Van Rie A, Warren RM, Beyers N, et al. Transmission of a multidrug-resistant tuberculosis strain resembling 'strain W' among noninstitutionalised, human immunodeficiency virus-seronegative patients. J Infect Dis 1999; 180:1608-1615.
6. Salomon N, Perlman DC. Multidrug resistant tuberculosis: globally with us for the long haul. Clin Infect Dis 1999; 21:93-95.
7. Frieden TR, Sherman LF, Maw KL, et al. Epidemiology and clinical outcomes: A multi-institutional outbreak of highly drug-resistant tuberculosis. JAMA 1996; 276:1229-1235.
8. Seaworth BJ. Multidrug-resistant tuberculosis. Infect Dis Clin North Am 2002; 16:73-105.
9. Moore M, Onotaro IM, McCray E, et al. Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA 1997; 278:833-837.
10. Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking proterase inhibitors or non-nucoleoside reverse transcriptase inhibitors. Centre for Disease Control and Prevention. Morb Mort Wkly Rep 2000; 49:185-189.
11. Bifani PJ, Pikaytis BB, Kapur V, et al. Origin and interstate spread of New York City Multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 1996; 275:452-457.
12. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328:527-532.
13. Sullivan EA, Kreiswirth B, Palumbo L, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995; 345:1148-1150.
14. Farmer P, Yong KJ. Community based approaches to the control of multidrug-resistant tuberculosis: Introducing DOTS-Plus. BMJ 1998; 317:671-674.
15. Johnson JL, Nunn AJ, Fourie PB. Effect of Mycobacterium vaccae (SRL172) immunotherpay on radiographic healing in tuberculosis. Int J Tuberc Lung Dis 2004; 8:1348-1354.
16. Marttila HJ, Soini H. Molecular detection of resistance to antituberculous therapy. Clin Lab Med 2003; 823-841.
17. Piatek AS, Telenti A, Murray MR, et al. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 2000; 44:103-110.
18. Albert H, Trollip AP, Mole RJ, et al. Rapid indication of multidrug-resistant tuberculosis from liquid cultures using FASTplaqueTB-RIF, a manual phage based test. Int J Tuberc Lung Dis 2002; 6:523-528.
19. Jacobs WR, Barletta RG, Udani R, et al. Rapid assessment of drug susceptibilities of mycobacterium tuberculosis by means of luciferase reporter phages. Science 1993; 260:819-822.
20. Centers for Disease Control and Prevention. Notice to readers. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. Morb Mort Wkly Report 2002; 51:214-215.
21. Tuberculous Research Center. Shortening short course chemotherapy. A randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian Journal of Tuberculosis 2002; 49:27-38.
22. Hu Y, Coates AR, Mitchison DA. Sterlilizing activities of fluoroquinolones against rifampin tolerant population of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47:653-657.
23. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169:334-335. This was a good preclinical study of moxifloxacin.
24. Valerio G, Braccciale P, Manisco V, et al. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother 2003; 15:66-70.
25. Ginsberg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis and resistance. Lancet Infect Dis 2003; 3:432-442.
26. Andries K, Verhasselt P, Guillemont J, et al. A diarlyquinoline drug active on the ATP synthase of mycobacterium tuberculosis. Science 2005; 307:223-227. This is an excellent article for readers interested in new TB drug development.
27. Stover CK, Warrener P, VanDevanter D, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405:962-966.
28. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant tuberculosis with interferon-γ via aerosol. Lancet Infect Dis 1997; 349:1513-1515.
29. McShane H, Pathan AA, Sander CR, et al. Recombinant modified vaccinia virus Ankara expressing Antigen 85 A boosts BCG primed and naturally acquired antimicycobacterial imminuty in humans. Nat Med 2004; 10:1240-1244.
30. Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci 2004; 9:1701-1719. Recommended for readers interested in immunotherapy.
31. Perelman M, Strelzov VP. Surgery for pulmonary tuberculosis. World J Surg 1997; 21:457-467.
32. Pomerantz M, Madsen L, Goble M, Iseman M. Surgical management of resistant mycobacterial tuberculosis and other mycobacterial pulmonary infections. Ann Thorac Surg 1991; 52:1108-1112.
33. Van Leuven M, De Groot M, Shean K, et al. Pulmonary resection as an adjunct in the treatment of multiple drug-resistant tuberculosis. Ann Thorac Surg 1997; 63:1368-1373.
34. Shiraishi Y, Nakajima Y, Katsuragi N, et al. Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis. J Thorac Cardiovasc Surg 2004; 128:523-528. This outlines the current thinking on a more aggressive strategy for surgical intervention.
35. Naidoo R, Reddi A. Lung resection for multidrug resistant tuberculosis. Asian Ann Thorac and Cardiovasc Surg 2005; 13:172-174. Current review on the role of surgery, confirming the benefits of surgery.
36. Takeda T, Maeda H, Hayakawa M, et al. Current surgical intervention for pulmonary tuberculosis. Ann Thorac Surg 2005; 79:959-963. This is an excellent overall review on the role of surgery for pulmonary tuberculosis, focussing mainly on the role of surgery in MDR TB.
37. Park SK, Lee CM, Heu JP, Song SD. A retrospective study for the outcome of pulmonary resection in 49 patients with multi-drug resistant tuberculosis. In J Tuberc Lung Dis 2002; 6:143-149.
38. Connery C, Knoetgen J, Anagnostopoulos C, Svitak M. Median sternotomy for pneumonectomy in patients with pulmonary complications of tuberculosis. Ann Thorac Surg 2003; 75:1613-1617.
39. Pomerantz BJ, Cleveland JC, Olson HK, Pomerantz M. Pulmonary resection for multi-drug resistant tuberculosis. J Thorac Cardiovasc Surg 2001; 121:448-453.
40. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multi-drug resistant tuberculosis. Am J Respir Crit Care Med 2004; 169:1103-1109. This provides a more balanced view in terms of the medical and surgical management of this group of patients.
41. Treasure RL, Seaworth BJ. Current role of surgery in Mycobacterium tuberculosis. Ann Thorac Surg 1995; 59:1405-1409.
42. Deschamps C, Bernard A, Nichols FC III, Allen MS, et al. Empyema and bronchopleural fistula after pneumonectomy: Factors affecting incidence. Ann Thorac Surg 2001; 72:243-248.
43. Abdool-Karim SS, Abdool-Karim O, Friedland G, et al. Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care. AIDS 2004; 18:975-979.